RT info:eu-repo/semantics/article
T1 Implementing HPV testing in 9 Latin American countries : the laboratory perspective as observed in the ESTAMPA study
A1 Rol, Mary Luz
A1 Picconi, María Alejandra
A1 Ferrera, Annabelle
A1 Sánchez, Gloria Inés
A1 Hernández, María de la Luz
A1 Lineros, Joana
A1 Peraza, Ana
A1 Brizuela, Marisol
A1 Mendoza Torres, Laura Patricia
A1 Mongelós Dacunte, Pamela Esther
A1 Cabrera, Yessy
A1 Rodríguez de la Peña, Margarita
A1 Correa, Rita Mariel
A1 Terán, Carolina
A1 Colque Reynaga, Deisy
A1 García, Laura
A1 Ramírez, Arianis Tatiana
A1 Hernández Nevarez, Pilar
A1 Doimi, Franco
A1 Ramón, María
A1 Arias Stella, Javier
A1 Zúñiga, Michael
A1 Villagra, Veronica
A1 Bobadilla Frizzola, María Liz
A1 Cardinal, Lucía
A1 Valls, Joan
A1 Lucas, Eric
A1 Baena, Armando
A1 Fleider, Laura
A1 Venegas, Gino
A1 Cruz Valdez, Aurelio
A1 Rodríguez, Guillermo
A1 Calderón, Alejandro
A1 Wiesner, Carolina
A1 Luciani, Silvana
A1 Broutet, Nathalie
A1 Herrero, Rolando
A1 Almonte, Maribel
A2 Universidad Nacional de Asunción. Instituto de Investigaciones en Ciencias de la Salud
AB Background: Replacement of cytology screening with HPV testing is recommended and essential for cervical cancer elimination. HPV testing for primary screening was implemented in 12 laboratories within 9 Latin American countries, as part of the ESTAMPA cervical cancer screening study. Our observations provide information on critical operational aspects for HPV testing implementation in diverse resource settings.Methods: We describe the implementation process of HPV testing in ESTAMPA, focusing on laboratory aspects. We assess the readiness of 12 laboratories to start HPV testing and their continuity capacity to maintain good quality HPV testing until end of recruitment or up to December 2021. Readiness was based on a checklist. Information from the study database; regular meetings and monitoring visits; and a questionnaire on laboratory operational aspects sent in May 2020 were used to assess continuity capacity. Compliance with seven basic requirements (readiness) and eight continuity requirements (continuity capacity) was scored (1 = compliant, 0 = not compliant) and totaled to classify readiness and continuity capacity as very limited, limited, moderate or high. Experiences, challenges, and enablers of the implementation process are also described.Results: Seven of 12 laboratories had high readiness, three moderate readiness, and of two laboratories new to HPV testing, one had limited readiness and the other very limited readiness. Two of seven laboratories with high readiness also showed high continuity capacity, one moderate continuity capacity, and the other four showed limited continuity capacity since they could not maintain good quality HPV testing over time. Among three laboratories with moderate readiness, one kept moderate continuity capacity and two reached high continuity capacity. The two laboratories new to HPV testing achieved high continuity capacity. Based on gained expertise, five laboratories have become part of national screening programs.Conclusion: High readiness of laboratories is an essential part of effective implementation of HPV testing. However, high readiness is insufficient to guarantee HPV testing high continuity capacity, for which a "culture of quality" should be established with regular training, robust monitoring and quality assurance systems tailored to local context. All efforts to strengthen HPV laboratories are valuable and crucial to guarantee effective implementation of HPV-based cervical screening.
PB Frontiers Media S.A.
YR 2022
FD 2022-11-17
LK http://hdl.handle.net/20.500.14066/4420
UL http://hdl.handle.net/20.500.14066/4420
LA eng
NO Rol, M. L., Picconi, M. A., Ferrera, A., Sánchez, G. I., Hernández, M. L., Lineros, J., Peraza, A., Brizuela, M., Mendoza, L., Mongelós, P., Cabrera, Y., Rodríguez de la Peña, M., Correa, R. M., Terán, C., Colque Reynaga, D., García, L., Ramírez, A. T., Hernández-Nevarez, P., Doimi, F., Ramón, M., … Almonte, M. (2022). Implementing HPV testing in 9 Latin American countries: The laboratory perspective as observed in the ESTAMPA study. Frontiers in medicine, 9, 1006038. https://doi.org/10.3389/fmed.2022.1006038
NO Correspondence: Maribel Almontealmontem@who.int
NO This article was submitted to Infectious Diseases - Surveillance, Prevention and Treatment, a section of the journal Frontiers in Medicine.
NO Consejo Nacional de Ciencia y Tecnología
DS MINDS@UW
RD 16-nov-2024